Phase II study of oral VP-16-213 in hepatocellular carcinoma

F. Cavalli, M. Rozencweig, J. Renard, A. Goldhirsch, H. H. Hansen

Research output: Contribution to journalArticlepeer-review


In a disease-oriented phase II study, 26 patients with hepatocellular carcinoma were treated with oral VP-16-213 at 120 mg/m2/day for 5 consecutive days, repeated every 3 weeks. Of 24 evaluable patients, 3 achieved partial remission (PR) for 12, 16 and 35 weeks respectively. Minor regression or stabilization of the disease (NC) was achieved in 8 patients for a median duration of 15 weeks. Patients with PR and NC experienced similar median survival (22 weeks), whereas non-responders had a median survival of less than 8 weeks. Results of this trial indicate that VP-16-213 has limited but definite anti-tumor activity in hepatocellular carcinoma.

Original languageEnglish
Pages (from-to)1079-1082
Number of pages4
JournalEuropean Journal of Cancer (1965)
Issue number10
Publication statusPublished - 1981

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Phase II study of oral VP-16-213 in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this